Sound Shore Management, an investment management firm, has released its investor letter for the fourth quarter of 2024. A ...

The financial results were actually positive, at the higher end of analysts' forecasts, but profit guidance for 2025 ...

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel ...

Detailed results presented at a medical congress help reinforce analyst expectations the drug, called duvakitug, will be competitive with other Crohn’s, colitis medicines in testing.

while Teva will handle commercialization of the product. Additionally, on January 13, 2025, Teva Pharmaceuticals International GmbH announced that they entered into an agreement with Formycon AG ...

The company will report earnings before the open on Jan. 29 Israel-based pharmaceutical giant Teva Pharmaceutical Industries Ltd (NYSE:TEVA) is preparing for its latest quarterly earnings report ...

product. Auvelity is approved in the U.S. for major depressive disorder. The litigation resulted from Teva submitting an Abbreviated New Drug Application to the U.S. Food and Drug Administration ...